Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for Lipoatrophy in HIV-1 Infected Patients
NCT00148850Phase 3Terminated
- Sponsor
- ANRS
- Start
- Feb 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HIV-associated lipodystrophy syndrome (HALS) comparing Pioglitazone with Placebo (2 arms). Primary endpoint: Evolution of limb fat using DEXA Scan at 48 weeks. Started Feb 2003; status: terminated.
02
Drugs
pioglitazone
03
Conditions
HIV-associated lipodystrophy syndrome (HALS)
Beyond the preview
Go deeper on NCT00148850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00148850.